MovDisordV3, Main, Exploration, bibRecord, 002473

A pilot study using nabilone for symptomatic treatment in Huntington's disease

Identifieur interne : 002473 ( Main/Exploration ); précédent : 002472; suivant : 002474

A pilot study using nabilone for symptomatic treatment in Huntington's disease

Auteurs : Adrienne Curtis [Royaume-Uni] ; Ian Mitchell [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Hugh Rickards [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2009-11-15.

RBID : ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF

Descripteurs français

Pascal (Inist)
- Cannabinoïde, Chorée de Huntington, Nabilone, Pathologie du système nerveux, Syndrome choréique, Traitement, Trouble psychiatrique.

English descriptors

KwdEn :
- Adult, Aged, Anti-Anxiety Agents (therapeutic use), Behavioral Symptoms (drug therapy), Behavioral Symptoms (etiology), Cannabinoid, Chorea, Cognition Disorders (drug therapy), Cognition Disorders (etiology), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Dronabinol (analogs & derivatives), Dronabinol (therapeutic use), Female, Humans, Huntington Disease (complications), Huntington Disease (drug therapy), Huntington disease, Huntington's disease, Male, Mental disorder, Middle Aged, Nabilone, Nervous system diseases, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects, Treatment, cannabinoids, chorea, nabilone, psychiatric symptoms.
MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , therapeutic use : Anti-Anxiety Agents, Dronabinol.
- complications : Huntington Disease.
- drug therapy : Behavioral Symptoms, Cognition Disorders, Huntington Disease.
- etiology : Behavioral Symptoms, Cognition Disorders.
- Adult, Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects.

Abstract

Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society

Url:

https://api.istex.fr/document/61E6C434C0A8437E3F399E156F16677D97B934DF/fulltext/pdf

DOI: 10.1002/mds.22809

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22809</idno>
<idno type="url">https://api.istex.fr/document/61E6C434C0A8437E3F399E156F16677D97B934DF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002E41</idno>
<idno type="wicri:Area/Istex/Curation">002E41</idno>
<idno type="wicri:Area/Istex/Checkpoint">001075</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19845035</idno>
<idno type="wicri:Area/PubMed/Corpus">001B27</idno>
<idno type="wicri:Area/PubMed/Curation">001B27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F76</idno>
<idno type="wicri:Area/Ncbi/Merge">002856</idno>
<idno type="wicri:Area/Ncbi/Curation">002856</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002856</idno>
<idno type="wicri:Area/Main/Merge">002D34</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0036269</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D09</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002010</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F99</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:Area/Main/Merge">003096</idno>
<idno type="wicri:Area/Main/Curation">002473</idno>
<idno type="wicri:Area/Main/Exploration">002473</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham School of Psychology, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-11-15">2009-11-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">15</biblScope>
<biblScope unit="page" from="2254">2254</biblScope>
<biblScope unit="page" to="2259">2259</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<idno type="DOI">10.1002/mds.22809</idno>
<idno type="ArticleID">MDS22809</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Behavioral Symptoms (drug therapy)</term>
<term>Behavioral Symptoms (etiology)</term>
<term>Cannabinoid</term>
<term>Chorea</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dronabinol (analogs & derivatives)</term>
<term>Dronabinol (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Huntington Disease (complications)</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington disease</term>
<term>Huntington's disease</term>
<term>Male</term>
<term>Mental disorder</term>
<term>Middle Aged</term>
<term>Nabilone</term>
<term>Nervous system diseases</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
<term>Treatment</term>
<term>cannabinoids</term>
<term>chorea</term>
<term>nabilone</term>
<term>psychiatric symptoms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cannabinoïde</term>
<term>Chorée de Huntington</term>
<term>Nabilone</term>
<term>Pathologie du   système nerveux</term>
<term>Syndrome choréique</term>
<term>Traitement</term>
<term>Trouble psychiatrique</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
</region>
<settlement><li>Birmingham</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
</region>
<name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002473 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002473 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF
   |texte=   A pilot study using nabilone for symptomatic treatment in Huntington's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A pilot study using nabilone for symptomatic treatment in Huntington's disease

A pilot study using nabilone for symptomatic treatment in Huntington's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.